# First Regular Session Seventy-first General Assembly STATE OF COLORADO

## **ENGROSSED**

LLS NO. R17-1181.01 Ashley Athey x2291

HR17-1009

#### **HOUSE SPONSORSHIP**

Pabon,

#### **House Committees**

### **HOUSE RESOLUTION 17-1009**

101 CONCERNING THE AWARENESS OF MENINGOCOCCAL DISEASE.

- WHEREAS, Meningococcal disease is any infection caused by the bacterium *Neisseria meningitidis*; and
- WHEREAS, Although 1 in 10 people are carriers for this bacteria with no signs or symptoms of disease, sometimes *Neisseria meningitidis* bacteria can cause illness; and
- WHEREAS, In the United States, there are approximately 800 to 1,500 cases of meningococcal disease that occur each year; and
- WHEREAS, 10 to 15 infected individuals out of 100 will die even when treated, while about 10 to 20 out of every 100 people who survive will suffer from serious morbidity, including loss of limbs and impacts to the nervous system; and
- WHEREAS, Infants under one year of age, as well as young adults between the ages of 16 and 23, are among those most commonly impacted by this disease; and

1 2	WHEREAS, Meningococcal disease is spread from person to person via the exchange of the bacteria through respiratory and throat
3	secretion during close or lengthy contact; and
4	WHEREAS, Community settings in which large groups of people
5	gather, like college campuses, can increase the risk of the spread of
6	meningococcal disease; and
7	WHEREAS, There are different strains or serogroups of Neisseria
8	meningitidis, with serogroups B, C, and Y accounting for most
9	meningococcal diseases in the United States; and
10	WHEREAS, There have been several recent outbreaks of
11	serogroup B meningococcal disease on college campuses, with some
12	cases resulting in death; and
13	WHEREAS, There are vaccines that help provide protection
14	against all three serogroups (B, C, and Y) commonly seen in the United
15	States; and
16	WHEREAS, Vaccination for serogroups A, C, W, and Y is
17	routinely recommended by the Centers for Disease Control and
18	Prevention; and
19	WHEREAS, The Centers for Disease Control and Prevention's
20	Advisory Committee on Immunization Practices recommends that
21	decisions to vaccinate adolescents and young adults 16 through 23 years
22	of age against serogroup B meningococcal disease should be made at the
23	individual level with health care providers; and
24	WHEREAS, It is critical that students, parents, educators, and
25	health care providers understand the dangers of serogroup B
26	meningococcal disease and are aware that a vaccine is available to
27	prevent disease resulting from this serogroup; now, therefore,
28	Be It Resolved by the House of Representatives of the Seventy-first
29	General Assembly of the State of Colorado:
30	(1) That the recent incidences of meningococcal disease have
31	served as a reminder of the critical role vaccinations play in helping to
32	prevent this devastating illness;

-2- 1009

(2) That we, the members of the Colorado House of Representatives, encourage and urge all private and public high schools, colleges, and universities in the state to take reasonable steps to provide information to all students and parents about meningococcal disease, explaining the different disease serogroups, symptoms, risks, and treatment;

- (3) That such information shall also include the notice of availability, benefits, risks, and limitations of all meningococcal vaccines receiving a recommendation from the Advisory Committee on Immunization Practices (ACIP), including Category A and Category B recommendations, with specific information as to those persons at higher risk for the disease; and
  - (4) That each private and public high school, college, and university shall recommend that current and entering students receive meningococcal vaccines in accordance with current ACIP guidelines.

-3-